Published: 23 April 2021

Committees

Comments on agenda items for the 66th meeting of the Medicines Classification Committee to be held on 11 May 2021

The Medicines Classification Committee and the Secretary wish to thank everyone for their valuable input and feedback.

A total of 16 submissions commenting on agenda items for the 66th meeting was received (PDF, 5.32 MB, 39 pages). Some submissions commented on more than one agenda item. One submission and some parts of the comments and have been withheld from publication for reasons described under clause 2b of the Official Information Act 1982.

Agenda Item 5.1b Ibuprofen 400mg

One comment was received about this agenda item.

Agenda Item 6.1 Allopurinol – proposed change to the prescription classification statement (Individual)

Nine comments were received about this agenda item.

Agenda Item 6.2 Choline Salicylate – proposed reclassification from general sale medicine to pharmacy only medicine (Medsafe)

Three comments were received about this agenda item

Agenda Item 6.3 Ibuprofen 300mg in powder form – proposed reclassification from prescription medicine to pharmacy only medicine (AFT Pharmaceuticals Ltd)

Three comments were received about this agenda item.

Agenda Item 6.4 Topical Oral Benzocaine, Tetracaine Hydrochloride (Amethocaine), Lidocaine (lignocaine) and Prilocaine – proposed reclassification from prescription medicine to prescription except when classification (Dental Council - New Zealand)

Three comments were received about this agenda item.

Agenda Item 6.5 Hyaluronidase – proposed reclassification from general sale medicine to prescription medicine (New Zealand Society of Cosmetic Medicine)

Three comments were received about this agenda item.